Article Information
History
- January 11, 2022.
Article Versions
- You are currently viewing Version 1 of this article (January 11, 2022 - 07:30).
- Version 2 (March 7, 2022 - 10:27).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Joseph A. Lewnard, PhD1,2,3,*,
- Vennis X. Hong, MPH4,
- Manish M. Patel, MD5,
- Rebecca Kahn, PhD5,
- Marc Lipsitch, DPhil5 and
- Sara Y. Tartof, PhD4,6,*
- 1Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
- 2Division of Infectious Diseases & Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
- 3Center for Computational Biology, College of Engineering, University of California, Berkeley, Berkeley, California 94720, United States
- 4Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California 91101, United States
- 5COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, 30329, United States
- 6Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California 91101, United States
- ↵*Addresses for correspondence: Joseph A. Lewnard, 2121 Berkeley Way, Berkeley, California 94720, jLewnard{at}berkeley.edu, 510-664-4050, Sara Y. Tartof, 100 South Los Robles, Pasadena, California 91101, Sara.Y.Tartof{at}kp.org, 626-564-3001
Posted January 11, 2022.
Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California
